Dry and Wet Age-Related Macular Degeneration | TreatmentTrends | US | 2015
TreatmentTrends: Dry/Wet Age-Related Macular Degeneration 2015 (US) is the fifth annual syndicated report series that offers a snapshot of dry and wet age-related macular degeneration (AMD) market dynamics and the competitive landscape through comprehensive primary research with retinal specialists and general ophthalmologists who personally administer anti-vascular endothelial growth factor (VEGF) injections. The report provides valuable insight into the current and anticipated treatment of patients with dry and wet AMD, with a particular focus on the administration of intravitreal anti-VEGF agents (i.e., off-label Avastin, Eylea, Lucentis). We also assess surveyed physicians’ perceptions of these wet AMD products—e.g., their advantages and disadvantages, ideal patient types, barriers to growth—and current detailing and messaging efforts for approved wet AMD brands. Respondents are asked about their awareness of products in development for dry or wet AMD and anticipated integration of these products in the treatment algorithm, as well as the potential for biosimilars in the wet AMD market.
